J 2018

Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage

TSIVGOULIS, Georgios, Duncan WILSON, Aristeidis H. KATSANOS, Joao SARGENTO-FREITAS, Claudia MARQUES-MATOS et. al.

Basic information

Original name

Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage

Authors

TSIVGOULIS, Georgios (300 Greece), Duncan WILSON (826 United Kingdom of Great Britain and Northern Ireland), Aristeidis H. KATSANOS (300 Greece), Joao SARGENTO-FREITAS (620 Portugal), Claudia MARQUES-MATOS (620 Portugal), Elsa AZEVEDO (620 Portugal), Tomohide ADACHI (392 Japan), Christian BRELIE (276 Germany), Yoshifusa AIZAWA (392 Japan), Hiroshi ABE (392 Japan), Hirofumi TOMITA (392 Japan), Ken OKUMURA (392 Japan), Joji HAGII (392 Japan), David J. SEIFFGE (756 Switzerland), Vasileios-Arsenios LIOUTAS (840 United States of America), Christopher TRAENKA (756 Switzerland), Panayiotis VARELAS (840 United States of America), Ghazala BASIR (124 Canada), Christos KROGIAS (276 Germany), Jan C. PURRUCKER (276 Germany), Vijay K. SHARMA (702 Singapore), Timolaos RIZOS (276 Germany), Robert MIKULÍK (203 Czech Republic, belonging to the institution), Oluwaseun A. SOBOWALE (826 United Kingdom of Great Britain and Northern Ireland), Kristian BARLINN (276 Germany), Hanne SALLINEN (246 Finland), Nitin GOYAL (840 United States of America), Shin-Joe YEH (158 Taiwan), Theodore KARAPANAYIOTIDES (300 Greece), Teddy Y. WU (554 New Zealand), Konstantinos VADIKOLIAS (300 Greece), Marc FERRIGNO (250 France), Georgios HADJIGEORGIOU (196 Cyprus), Rik HOUBEN (528 Netherlands), Sotirios GIANNOPOULOS (300 Greece), Floris H. B. M. SCHREUDER (528 Netherlands), Jason J. CHANG (840 United States of America), Luke A. PERRY (36 Australia), Maximilian MEHDORN (276 Germany), Joao-Pedro MARTO (620 Portugal), Joao PINHO (620 Portugal), Jun TANAKA (392 Japan), Marion BOULANGER (826 United Kingdom of Great Britain and Northern Ireland), Rustam Al-Shahi SALMAN (826 United Kingdom of Great Britain and Northern Ireland), Hans R. JAEGER (826 United Kingdom of Great Britain and Northern Ireland), Clare SHAKESHAFT (826 United Kingdom of Great Britain and Northern Ireland), Yusuke YAKUSHIJI (36 Australia), Philip M. C. CHOI (36 Australia), Julie STAALS (528 Netherlands), Charlotte CORDONNIER (250 France), Jiann-Shing JENG (158 Taiwan), Roland VELTKAMP (826 United Kingdom of Great Britain and Northern Ireland), Dar DOWLATSHAHI (124 Canada), Stefan T. ENGELTER (756 Switzerland), Adrian R. PARRY-JONES (826 United Kingdom of Great Britain and Northern Ireland), Atte MERETOJA (246 Finland), Panayiotis D. MITSIAS (840 United States of America), Andrei V. ALEXANDROV (840 United States of America), Gareth AMBLER (826 United Kingdom of Great Britain and Northern Ireland) and David J. WERRING (826 United Kingdom of Great Britain and Northern Ireland, guarantor)

Edition

Annals of neurology, Hoboken, John Wiley & Sons, 2018, 0364-5134

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 9.496

RIV identification code

RIV/00216224:14110/18:00105323

Organization unit

Faculty of Medicine

UT WoS

000450819800007

Keywords in English

vitamin K antagonists; intracerebral hemorrhage

Tags

Tags

International impact, Reviewed
Změněno: 10/2/2019 16:35, Soňa Böhmová

Abstract

V originále

Objective Methods Whether intracerebral hemorrhage (ICH) associated with non-vitamin K antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH associated with vitamin K antagonists (VKA-ICH) is uncertain. We performed a systematic review and individual patient data meta-analysis of cohort studies comparing clinical and radiological outcomes between NOAC-ICH and VKA-ICH patients. The primary outcome measure was 30-day all-cause mortality. All outcomes were assessed in multivariate regression analyses adjusted for age, sex, ICH location, and intraventricular hemorrhage extension. Results Interpretation We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH patients (mean age = 77 years, 52.5% females). The 30-day mortality was similar between NOAC-ICH and VKA-ICH (24.3% vs 26.5%; hazard ratio = 0.94, 95% confidence interval [CI] = 0.67-1.31). However, in multivariate analyses adjusting for potential confounders, NOAC-ICH was associated with lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regression coefficient = -2.83, 95% CI = -5.28 to -0.38), lower likelihood of severe stroke (NIHSS > 10 points) on admission (odds ratio [OR] = 0.50, 95% CI = 0.30-0.84), and smaller baseline hematoma volume (linear regression coefficient = -0.24, 95% CI = -0.47 to -0.16). The two groups did not differ in the likelihood of baseline hematoma volume < 30cm(3) (OR = 1.14, 95% CI = 0.81-1.62), hematoma expansion (OR = 0.97, 95% CI = 0.63-1.48), in-hospital mortality (OR = 0.73, 95% CI = 0.49-1.11), functional status at discharge (common OR = 0.78, 95% CI = 0.57-1.07), or functional status at 3 months (common OR = 1.03, 95% CI = 0.75-1.43). Although functional outcome at discharge, 1 month, or 3 months was comparable after NOAC-ICH and VKA-ICH, patients with NOAC-ICH had smaller baseline hematoma volumes and less severe acute stroke syndromes. Ann Neurol 2018;84:702-712